1996
DOI: 10.1093/clinids/22.2.315
|View full text |Cite
|
Sign up to set email alerts
|

Amphotericin B Lipid Complex Compared with Amphotericin B in the Treatment of Cryptococcal Meningitis in Patients with AIDS

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
85
1
2

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 178 publications
(91 citation statements)
references
References 10 publications
3
85
1
2
Order By: Relevance
“…Electrolyte disturbances may be exacerbated by co-administration of thiazides and loop diuretics. Toxicity appears to be reduced for the lipid formulations (liposomal amphotericin B and amphotericin B lipid complex) [51][52][53]. These formulations do not appear to be more toxic in elderly patients than in younger patients and efficacy appears to be similar [54,55].…”
Section: Amphotericin Bmentioning
confidence: 97%
“…Electrolyte disturbances may be exacerbated by co-administration of thiazides and loop diuretics. Toxicity appears to be reduced for the lipid formulations (liposomal amphotericin B and amphotericin B lipid complex) [51][52][53]. These formulations do not appear to be more toxic in elderly patients than in younger patients and efficacy appears to be similar [54,55].…”
Section: Amphotericin Bmentioning
confidence: 97%
“…However, many patients in the latter group maintained positive culture for cryptococcus at the end of the treatment. (26) In uncontrolled studies of patients with opportunistic infections, ABLC showed an efficacy of 42%, 67% and 100% in aspergillosis cases, of 66%, 67% and 100% in candidiasis cases, of 71% in zygomycosis cases, and of 82% in fusariosis cases. (27)(28)(29) …”
Section: Amphotericin B Lipid Complexmentioning
confidence: 99%
“…With the exception of histoplasmosis, in which liposomal amphotericin B has been shown to provide a greater percentage of favorable responses, (47) the efficacy of the new formulations is similar to that of conventional amphotericin B in patients with cryptococosis, (17,26) candidiasis, (10) aspergillosis, (23) or (empirical treatment of) neutropenia with persistent fever. (16,22) Notwithstanding these observations, it is accepted that one of the indications for the use of lipid preparations is presumed failure of amphotericin B desoxycholate treatment, using the criterion of the lack of a favorable response after an accumulated dose of 500 mg. (48) In that case, it is supposed that the fungus is susceptible and, especially in the empirical treatment of immunosuppressed patients, daily doses greater than those recommended for conventional amphotericin B but within the therapeutic range recommended for L-Amb, ABCD and ABLC, are used.…”
Section: Clinical Use Of New Antifungal Agents Lipid Formulations Of mentioning
confidence: 99%
“…5FC levels should be monitored, where available, and its dose should be adjusted in renal impairment as drug accumulation increases the risk of bone marrow toxicity (Perfect et al 2010). AmBd-induced anemia is a significant and less well-recognized adverse effect, resulting in a drop in hemoglobin from baseline of 2-3 g/dL (Joly et al 1996;Sharkey et al 1996;Leenders et al 1998;Bicanic et al 2008), which may necessitate transfusion. Adverse effects are reversible on stopping treatment (Bicanic et al 2008).…”
Section: Minimize Drug Toxicitymentioning
confidence: 99%